2019
The many challenges of developing drugs appropriately formulated for children are compounded by a series of market factors that make these efforts costly and complex, discouraging drug manufacturers – especially generic drug manufacturers – from prioritizing investments in new paediatric treatment options.
In alignment with the Rome Action Plan, the IAS Industry Liaison Forum (ILF) developed a policy brief exploring the opportunities of advance procurement as a pragmatic approach for the largest ARV buyers – most notably national governments (particularly the Government of South Africa),